Premium
Synergistic activity of 1‐(1‐naphthylmethyl)‐piperazine with ciprofloxacin against clinically resistant Staphylococcus aureus , as determined by different methods
Author(s) -
Li L.,
Li Z.,
Guo N.,
Jin J.,
Du R.,
Liang J.,
Wu X.,
Wang X.,
Liu M.,
Jin Q.,
Yu L.
Publication year - 2011
Publication title -
letters in applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.698
H-Index - 110
eISSN - 1472-765X
pISSN - 0266-8254
DOI - 10.1111/j.1472-765x.2011.03010.x
Subject(s) - staphylococcus aureus , microbiology and biotechnology , ciprofloxacin , micrococcaceae , piperazine , chemistry , biology , bacteria , antibacterial agent , antibiotics , organic chemistry , genetics
Aims: To evaluate the interaction of 1‐(1‐naphthylmethyl)‐piperazine (NMP) and ciprofloxacin (CPFX) in vitro against fluoroquinolone (FQ)‐resistant clinical isolates of methicillin‐resistant Staphylococcus aureus (MRSA) . Methods and Results: The in vitro interaction of NMP and CPFX in 12 FQ‐resistant clinical isolates of MRSA was assessed using a checkerboard microdilution method. In the study, a synergistic antimicrobial effect between NMP and CPFX was observed in all 12 FQ‐resistant strains tested, as determined by the fractional inhibitory concentration index (FICI), and in 10 strains using Δ E models. No antagonistic activity was observed in any of the strains tested. These positive interactions were also confirmed using the time–killing test and agar diffusion assay for the selected strain, MRSA 1862; synergistic activity was observed when NMP was combined with the first‐line antimicrobial agent CPFX against Staph. aureus . Conclusions: Synergistic activity between NMP and CPFX against clinical isolates of FQ‐resistant Staph. aureus was observed in vitro . Significance and Impact of the Study: This report might provide alternative methods to reduce the resistance of Staph. aureus to CPFX.